Clinical practice guideline for the management of rheumatoid arthritis in Spain.

GUIDELINE TITLE
Clinical practice guideline for the management of rheumatoid arthritis in Spain.

BIBLIOGRAPHIC SOURCE(S)
GUIPCAR Group. Clinical practice guideline for the management of rheumatoid arthritis in Spain. Madrid: Spanish Society of Rheumatology; 2007 Mar. 301 p. [1260 references]

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: GUIPCAR Group. Clinical practice guideline for the management of rheumatoid arthritis. Madrid: Spanish Society of Rheumatology; 2001. 170 p.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory information has been released:

July 14, 2009 - Sirolimus (Rapamune), Cyclosporine (Sandimmune or Neoral and generics), Mycophenolate mofetil (Cellcept and generics), Mycophenolic acid (Myfortic): The U.S. Food and Drug Administration (FDA) is requiring the makers of certain immunosuppressant drugs to update their labeling to reflect that immunosuppressed patients are at increased risk for opportunistic infections, such as activation of latent viral infections, including BK virus-associated nephropathy.
September 11, 2008 - Rituxan (Rituximab): Genentech informed healthcare professionals of revisions to prescribing information for Rituxan regarding a case of progressive multifocal leukoencephalopathy (PML) leading to death in a patient with rheumatoid arthritis who received Rituxan in a long-term safety extension clinical study.

abrir aquí para acceder al documento NGC AHRQ completo:
Clinical practice guideline for the management of rheumatoid arthritis in Spain.